Bone Biologics
BBLG
7 hedge funds and large institutions have $36.7K invested in Bone Biologics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
1,901% more capital invested
Capital invested by funds: $1.83K → $36.7K (+$34.8K)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
75% more funds holding
Funds holding: 4 → 7 (+3)
0.65% more ownership
Funds ownership: 0.08% → 0.73% (+0.65%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$27.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.2K |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
+$583 |
| 4 |
Citigroup
New York
|
+$522 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$119 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DS
1
DRW Securities
Chicago,
Illinois
| $30.8K | +$27.9K | +11,027 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $4.08K | +$3.2K | +1,264 | +632% |
|
|
SS
3
SBI Securities
Tokyo,
Japan
| $642 | +$583 | +230 | New |
|
|
4
Citigroup
New York
| $575 | +$522 | +206 | New |
|
|
CS
5
Clear Street
New York
| $385 | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $184 | -$119 | -47 | -42% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $39 | +$25 | +10 | +250% |
|
BBLG Hedge Fund Activity: Q3 2025 in Review
7 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q3 2025, worth a combined $36.7K — up 1,901% from $1.83K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BBLG positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $27.9K. The largest seller was UBS Group, cutting an estimated $119.
- 7 institutional investors held Bone Biologics (BBLG) as of Q3 2025, up from 4 in Q2 2025.
- Funds reported $36.7K of Bone Biologics stock for Q3 2025, up 1,901% quarter-over-quarter.
- 3 funds opened new Bone Biologics positions in Q3 2025 and 0 closed out, a net change of +3 holders.
- The largest Bone Biologics buyer in Q3 2025 was DRW Securities, an estimated $27.9K added.
- The largest Bone Biologics seller in Q3 2025 was UBS Group, an estimated $119 sold.
Based on aggregated 13F filings for Q3 2025.